Recent Research Analysts’ Ratings Updates for GlycoMimetics (GLYC)

GlycoMimetics (NASDAQ: GLYC) recently received a number of ratings updates from brokerages and research firms:

• 4/7/2025 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/30/2025 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/22/2025 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/21/2025 – GlycoMimetics is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 3/14/2025 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/6/2025 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/26/2025 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/18/2025 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/10/2025 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

GlycoMimetics Stock Up 1.2 %

Shares of NASDAQ GLYC traded up $0.00 during trading hours on Thursday, hitting $0.19. The company’s stock had a trading volume of 155,769 shares, compared to its average volume of 6,737,220. GlycoMimetics, Inc. has a 12 month low of $0.14 and a 12 month high of $2.57. The business has a 50-day simple moving average of $0.26 and a 200-day simple moving average of $0.26.

GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings data on Thursday, February 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Sell-side analysts forecast that GlycoMimetics, Inc. will post -0.08 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GLYC. Caxton Corp bought a new stake in shares of GlycoMimetics during the 4th quarter valued at about $51,000. ADAR1 Capital Management LLC grew its holdings in shares of GlycoMimetics by 626.1% during the 4th quarter. ADAR1 Capital Management LLC now owns 331,827 shares of the biotechnology company’s stock worth $83,000 after acquiring an additional 286,127 shares during the period. Jefferies Financial Group Inc. bought a new position in shares of GlycoMimetics in the 4th quarter worth approximately $106,000. Wellington Management Group LLP purchased a new position in shares of GlycoMimetics in the 4th quarter valued at approximately $352,000. Finally, VR Adviser LLC bought a new stake in shares of GlycoMimetics during the fourth quarter valued at approximately $747,000. 75.19% of the stock is owned by hedge funds and other institutional investors.

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.